Clinical significance of the determinations of serum MMP-13 and TGF-β1 in chronic liver disease

Objective To determine the matrix metalloproteinase-13( MMP-13) and transform growth factor beta 1( TGF-β1) in patients with chronic liver disease,and to analyze the correlation and clinical significance. Methods A total of 50 chronic hepatitis patients,50 cirrhosis patients,60 liver carcinoma patients and 50 healthy subjects( healthy control group) were enrolled and determined for MMP-13 and TGF-β1 by enzyme-linked immunosorbent assay( ELISA). Results The MMP-13 in the chronic hepatitis patients,cirrhosis patients,liver carcinoma patients and healthy controls were 287. 05 ± 29. 80,328. 04 ± 62. 03,329. 02 ± 70. 04 and( 279. 03 ± 32. 80) ng / L. The TGF-β1 in the chronic hepatitis patients,cirrhosis patients,liver carcinoma patients and healthy controls were 0. 99 ± 0. 11,0. 96 ± 0. 12,2. 22 ± 1. 08 and( 0. 65 ± 0. 09) μg / L. The expressions of MMP-13 and TGF-β1 in patients with chronic hepatitis,cirrhosis and liver carcinoma were higher than those in healthy controls. The serum MMP-13 in cirrhosis and liver carcinoma patients were much higher than those in chronic hepatitis patients( P 0. 01). The TGF-β1 in liver carcinoma patients was higher than those in cirrhosis and chronic hepatitis patients( P 0. 01). In comparison to healthy controls,the TGF-β1 in the cirrhosis and chronic hepatitis patients had no statistical significance( P 0. 05).Conclusions In the development of chronic liver diseases,the MMP-13 and TGF-β1 express excessively. The dynamic analysis of their levels may be helpful to the diagnosis and monitoring of chronic disease.